Mirati Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch MRTX and buy or sell other stocks, ETFs, and their options commission-free!About MRTX
Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer.
CEOCharles M. Baum, MD, PhD
CEOCharles M. Baum, MD, PhD
Employees—
Employees—
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded1995
Founded1995
Employees—
Employees—
MRTX Key Statistics
Market cap4.12B
Market cap4.12B
Price-Earnings ratio-4.80
Price-Earnings ratio-4.80
Dividend yield—
Dividend yield—
Average volume2.31M
Average volume2.31M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$64.41
52 Week high$64.41
52 Week low$27.30
52 Week low$27.30
Stock Snapshot
Mirati Therapeutics(MRTX) stock is priced at $58.70, giving the company a market capitalization of 4.12B. It carries a P/E multiple of -4.80.
Mirati Therapeutics(MRTX) stock opened on 2026-01-04 at —. The price climbed to — and dipped to —.
The Mirati Therapeutics(MRTX)'s current trading volume is 0, compared to an average daily volume of 2.31M.
During the past year, Mirati Therapeutics(MRTX) stock moved between $27.30 at its lowest and $64.41 at its peak.
During the past year, Mirati Therapeutics(MRTX) stock moved between $27.30 at its lowest and $64.41 at its peak.
People also own
Based on the portfolios of people who own MRTX. This list is generated using Robinhood data, and it’s not a recommendation.